The anti-TNF-α antibody infliximab indirectly regulates PECAM-1 gene expression in two models of in vitro blood cell activation

Laboratory Investigation

Volumn 92, Issue 2, 2012, Pages 166-177

  Moriconi, Federico ^a   Malik, Ihtzaz Ahmed ^a   Amanzada, Ahmad ^a   Blaschke, Martina ^a   Raddatz, Dirk ^a   Khan, Sajjad ^a   Ramadori, Giuliano ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

adhesion molecules; cytokines; granulocytes; inflammatory bowel disease; infliximab; peripheral blood leukocytes

Indexed keywords

CD31 ANTIGEN; GAMMA INTERFERON; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; LIPOPOLYSACCHARIDE; MESSENGER RNA; PHYTOHEMAGGLUTININ; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; BLOOD CELL; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; GENE EXPRESSION REGULATION; GRANULOCYTE; HUMAN; HUMAN CELL; LEUKOCYTE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD31; BASE SEQUENCE; BLOTTING, WESTERN; CELLS, CULTURED; CYTOKINES; DNA PRIMERS; GASTROINTESTINAL AGENTS; GENE EXPRESSION REGULATION; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LEUKOCYTES; MODELS, THEORETICAL; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84856430424     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2011.160     Document Type: Article

References (65)

1. Eksteen B, Liaskou E, Adams DH. Lymphocyte homing and its role in the pathogenesis of IBD. Inflamm Bowel Dis 2008;14:1298-1312.
2. Lekstrom-Himes JA, Gallin JI. Immunodeficiency diseases caused by defects in phagocytes. N Engl J Med 2000;343:1703-1714.
3. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 2006;6:173-182. (Pubitemid 43290987)
4. McDonald B, Pittman K, Menezes GB, et al. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 2010;330: 362-366.
5. Guerrant RL, Araujo V, Soares E, et al. Measurement of fecal lactoferrin as a marker of fecal leukocytes. J Clin Microbiol 1992;30:1238-1242.
6. Woywodt A, Ludwig D, Neustock P, et al. Mucosal cytokine expression, cellular markers and adhesion molecules in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1999;11:267-276. (Pubitemid 29286680)
7. Smiljanovic B, Grun JR, Steinbrich-Zollner M, et al. Defining TNF-alphaand LPS-induced gene signatures in monocytes to unravel the complexity of peripheral blood transcriptomes in health and disease. J Mol Med 2010;88:1065-1079.
8. Shah VO, Ferguson JE, Hunsaker LA, et al. Natural products inhibit LPSinduced activation of pro-inflammatory cytokines in peripheral blood mononuclear cells. Nat Prod Res 2010;24:1177-1188.
9. Batliwalla FM, Baechler EC, Xiao X, et al. Peripheral blood gene expression profiling in rheumatoid arthritis. Genes Immun 2005;6: 388-397. (Pubitemid 43090514)
10. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003;100:2610-2615. (Pubitemid 36297546)
11. Raddatz D, Bockemuhl M, Ramadori G. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol 2005;17:547-557. (Pubitemid 40592713)
12. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-1035.
13. Baert FJ, D'Haens GR, Peeters M, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:22-28. (Pubitemid 29013489)
14. Olsen T, Cui G, Goll R, et al. Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis. Scand J Gastroenterol 2009;44:727-735.
15. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301:418-426. (Pubitemid 34429950)
16. Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999;163:1521-1528. (Pubitemid 29352775)
17. Ohshima S, Saeki Y, Mima T, et al. Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy. J Clin Immunol 1999;19:305-313. (Pubitemid 29489396)
18. Agnholt J, Dahlerup JF, Kaltoft K. The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures. Cytokine 2003;23:76-85. (Pubitemid 36945392)
19. Moriconi F, Raddatz D, Ho NA, et al. Quantitative gene expression of cytokines in peripheral blood leukocytes stimulated in vitro: modulation by the anti-tumor nerosis factor-alpha antibody infliximab and comparison with the mucosal cytokine expression in patients with ulcerative colitis. Transl Res 2007;150:223-232. (Pubitemid 47444612)
20. Lugering A, Schmidt M, Lugering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121: 1145-1157. (Pubitemid 33022095)
21. Ringheanu M, Daum F, Markowitz J, et al. Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease. Inflamm Bowel Dis 2004;10: 801-810. (Pubitemid 39545226)
22. Neubauer K, Lindhorst A, Tron K, et al. Decrease of PECAM-1- geneexpression induced by proinflammatory cytokines IFN-gamma and IFN-alpha is reversed by TGF-beta in sinusoidal endothelial cells and hepatic mononuclear phagocytes. BMC Physiol 2008;8:9.
23. Neubauer K, Ritzel A, Saile B, et al. Decrease of platelet-endothelial cell adhesion molecule 1-gene-expression in inflammatory cells and in endothelial cells in the rat liver following CCl(4)-administration and in vitro after treatment with TNFalpha. Immunol Lett 2000;74:153-164.
24. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 1968;97:77-89.
25. Dudas J, Mansuroglu T, Batusic D, et al. Thy-1 is an in vivo and in vitro marker of liver myofibroblasts. Cell Tissue Res 2007;329:503-514. (Pubitemid 47231300)
26. Malik IA, Moriconi F, Sheikh N, et al. Single-dose gamma-irradiation induces up-regulation of chemokine gene expression and recruitment of granulocytes into the portal area but not into other regions of rat hepatic tissue. Am J Pathol 2010;176:1801-1815.
27. Herbst H, Heinrichs O, Schuppan D, et al. Temporal and spatial patterns of transin/stromelysin RNA expression following toxic injury in rat liver. Virchows Arch B Cell Pathol Incl Mol Pathol 1991;60: 295-300.
28. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979;76:4350-4354. (Pubitemid 9256559)
29. Sartor RB. Innate immunity in the pathogenesis and therapy of IBD. J Gastroenterol 2003;38(Suppl 15):43-47. (Pubitemid 36442885)
30. Smith PD, Ochsenbauer-Jambor C, Smythies LE. Intestinal macrophages: unique effector cells of the innate immune system. Immunol Rev 2005;206:149-159. (Pubitemid 41105168)
31. Smythies LE, Sellers M, Clements RH, et al. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest 2005;115:66-75. (Pubitemid 40385506)
32. Yeruva S, Ramadori G, Raddatz D. NF-kappaB-dependent synergistic regulation of CXCL10 gene expression by IL-1beta and IFN-gamma in human intestinal epithelial cell lines. Int J Colorectal Dis 2008;23: 305-317.
33. Atreya R, Neurath MF. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol 2005;28:187-196.
34. Hosokawa T, Kusugami K, Ina K, et al. Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease. J Gastroenterol Hepatol 1999;14:987-996. (Pubitemid 29487295)
35. Kooijman R, Devos S, Hooghe-Peters E. Inhibition of in vitro cytokine production by human peripheral blood mononuclear cells treated with xenobiotics: implications for the prediction of general toxicity and immunotoxicity. Toxicol In Vitro 2010;24:1782-1789.
36. Yaqub S, Solhaug V, Vang T, et al. A human whole blood model of LPSmediated suppression of T cell activation. Med Sci Monit 2003;9:BR120-BR126. (Pubitemid 36389386)
37. Klotz L, Schmidt M, Giese T, et al. Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J Immunol 2005;175:4948-4955. (Pubitemid 41456376)
38. Wong M, Ziring D, Korin Y, et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol 2008;126:121-136.
39. Lichtenstein GR, Bala M, Han C, et al. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis 2002;8:237-243. (Pubitemid 34784975)
40. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009;58:492-500.
41. Cooper HS, Murthy S, Kido K, et al. Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, B-catenin and p53 expression and the role of inflammation. Carcinogenesis 2000;21:757-768. (Pubitemid 30214034)
42. Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7:251-259.
43. Brennan FM, Chantry D, Jackson A, et al. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2:244-247. (Pubitemid 19180612)
44. Wasmuth HE, Tacke F, Trautwein C. Chemokines in liver inflammation and fibrosis. Semin Liver Dis 2010;30:215-225.
45. Kansas GS. Selectins and their ligands: current concepts and controversies. Blood 1996;88:3259-3287. (Pubitemid 26365560)
46. Dangerfield J, Larbi KY, Huang MT, et al. PECAM-1 (CD31) homophilic interaction up-regulates alpha6beta1 on transmigrated neutrophils in vivo and plays a functional role in the ability of alpha6 integrins to mediate leukocyte migration through the perivascular basement membrane. J Exp Med 2002;196:1201-1211. (Pubitemid 35304186)
47. Sans M, Panes J, Ardite E, et al. VCAM-1 and ICAM-1 mediate leukocyteendothelial cell adhesion in rat experimental colitis. Gastroenterology 1999;116:874-883. (Pubitemid 29153535)
48. Huang MT, Larbi KY, Scheiermann C, et al. ICAM-2 mediates neutrophil transmigration in vivo: evidence for stimulus specificity and a role in PECAM-1-independent transmigration. Blood 2006;107:4721-4727. (Pubitemid 43882622)
49. Su WH, Chen HI, Jen CJ. Differential movements of VE-cadherin and PECAM-1 during transmigration of polymorphonuclear leukocytes through human umbilical vein endothelium. Blood 2002;100: 3597-3603. (Pubitemid 35303928)
50. Schenkel AR, Mamdouh Z, Chen X, et al. CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat Immunol 2002;3:143-150. (Pubitemid 34141444)
51. Jackson DE. The unfolding tale of PECAM-1. FEBS Lett 2003;540:7-14.
52. Mamdouh Z, Chen X, Pierini LM, et al. Targeted recycling of PECAM from endothelial surface-connected compartments during diapedesis. Nature 2003;421:748-753. (Pubitemid 36227626)
53. Privratsky JR, Newman DK, Newman PJ. PECAM-1: conflicts of interest in inflammation. Life Sci 2010;87:69-82.
54. Thompson RD, Noble KE, Larbi KY, et al. Platelet-endothelial cell adhesion molecule-1 (PECAM-1)-deficient mice demonstrate a transient and cytokine-specific role for PECAM-1 in leukocyte migration through the perivascular basement membrane. Blood 2001;97:1854-1860. (Pubitemid 32217254)
55. Bogen S, Pak J, Garifallou M, et al. Monoclonal antibody to murine PECAM-1 (CD31) blocks acute inflammation in vivo. J Exp Med 1994;179:1059-1064. (Pubitemid 24065668)
56. Newman PJ. The biology of PECAM-1. J Clin Invest 1997;100:S25-S29. (Pubitemid 28009542)
57. Vestweber D. Adhesion and signaling molecules controlling the transmigration of leukocytes through endothelium. Immunol Rev 2007;218:178-196. (Pubitemid 47052303)
58. DeLisser HM, Newman PJ, Albelda SM. Molecular and functional aspects of PECAM-1/CD31. Immunol Today 1994;15:490-495. (Pubitemid 24316016)
59. Romer LH, McLean NV, Yan HC, et al. IFN-gamma and TNF-alpha induce redistribution of PECAM-1 (CD31) on human endothelial cells. J Immunol 1995;154:6582-6592.
60. Neubauer K, Ritzel A, Saile B, et al. Decrease of platelet-endothelial cell adhesion molecule 1-gene-expression in inflammatory cells and in endothelial cells in the rat liver following CCl(4)- administration and in vitro after treatment with TNFalpha. Immunol Lett 2000;74:153-164.
61. Stockinger H, Gadd SJ, Eher R, et al. Molecular characterization and functional analysis of the leukocyte surface protein CD31. J Immunol 1990;145:3889-3897.
62. Zehnder JL, Hirai K, Shatsky M, et al. The cell adhesion molecule CD31 is phosphorylated after cell activation. Down-regulation of CD31 in activated T lymphocytes. J Biol Chem 1992;267:5243-5249.
63. Stewart RJ, Kashour TS, Marsden PA. Vascular endothelial platelet endothelial adhesion molecule-1 (PECAM-1) expression is decreased by TNF-alpha and IFN-gamma. Evidence for cytokine-induced destabilization of messenger ribonucleic acid transcripts in bovine endothelial cells. J Immunol 1996;156:1221-1228.
64. Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, et al. TGF-beta signaling in vascular fibrosis. Cardiovasc Res 2007;74: 196-206.
65. Teraoka H, Sawada T, Nishihara T, et al. Enhanced VEGF production and decreased immunogenicity induced by TGF-beta 1 promote liver metastasis of pancreatic cancer. Br J Cancer 2001;85:612-617. (Pubitemid 32808288)